3-(1-Methylpyrrolidin-2-yl)pyridine 分子结构式
HCID942

3-(1-Methylpyrrolidin-2-yl)pyridine

C10H14N2162.23 g/molCAS 22083-74-5

IDENTITY

结构与身份

标准SMILES
CN1CCCC1c1cccnc1
InChIKey
SNICXCGAKADSCV-UHFFFAOYSA-N
分子式
C10H14N2
平均分子量
162.23 g/mol
单同位素质量
162.11569846

COMPUTED

结构计算性质

已同步
XLogP
1.2
极性表面积
16.1 Ų
氢键供体
0
氢键受体
2
可旋转键
1
重原子
12
形式电荷
0
复杂度
147

PROPERTIES

实验与物化性质

Kovats Retention Index

1358

1884

GHS

GHS分类

GHS Classification

Danger

H301 (92.7%): Toxic if swallowed [Danger Acute toxicity, oral];H310 (100%): Fatal in contact with skin [Danger Acute toxicity, dermal];H411 (100%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]

P262, P264, P270, P273, P280, P301+P316, P302+P352, P316, P321, P330, P361+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

HAZARDS

危害信息

Hazard Classes and Categories

Acute Tox. 3 (92.7%);Acute Tox. 2 (100%);Aquatic Chronic 2 (100%)

TOXICITY

毒理信息

Treatment

Other supportive measures include diazepam or barbiturates for seizures, atropine for excessive bronchial secretions or diarrhea, respiratory support for respiratory failure, and vigorous fluid support for hypotension and cardiovascular collapse. (L1712)

Health Effects

Nicotine has mood-altering effects that may include relaxation, sharpness, calmness, and alertness. It may act as a stimulant or sedative/pain killer, depending on the dosage. (L327)

Exposure Routes

Oral (L327) ; Inhalation (L327) Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.

Toxicity Summary

Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allows more calcium to enter the axon terminal. Calcium stimulates vesicle trafficking towards the plasma membrane and the release of dopamine into the synapse. Dopamine binding to its receptors is responsible the euphoric and addictive properties of nicotine. Nicotine also binds to nicotinic acetylcholine receptors on the chromaffin cells in the adrenal medulla. Binding opens the ion channel allowing influx of sodium, causing depolarization of the cell, which activates voltage-gated calcium channels. Calcium triggers the release of epinephrine from intracellular vesicles into the bloodstream, which causes vasoconstriction, increased blood pressure, increased heart rate, and increased blood sugar.

Signs and Symptoms

Symptoms of overdose include nausea, abdominal pain, vomiting, diarrhea, diaphoresis, flushing, dizziness, disturbed hearing and vision, confusion, weakness, palpitations, altered respiration and hypotension.

Carcinogen Classification

No indication of carcinogenicity to humans (not listed by IARC).

Toxicity Data

LD50: 140 mg/kg (Dermal, Rat) LD50: 25 mg/kg (Subcutaneous, Rat) LD50: 5900 ug/kg (Intraperitoneal, Mouse) LD50: 2.8 mg/kg (Intravenous, Rat) (T80) LD50: 24 mg/kg (Oral, Mouse) (T18)

PHARMACOLOGY

药理信息

Metabolism/Metabolites

Nicotine has known human metabolites that include Nicotine N-glucuronide.

As nicotine enters the body, it is distributed quickly through the bloodstream and can cross the blood-brain barrier. On average it takes about seven seconds for the substance to reach the brain when inhaled. The half life of nicotine in the body is around two hours. Nicotine is metabolized in the liver by cytochrome P450 enzymes (mostly CYP2A6, and also by CYP2B6). A major metabolite is cotinine. Other primary metabolites include nicotine N'-oxide, nornicotine, nicotine isomethonium ion, 2-hydroxynicotine and nicotine glucuronide. (L327) Route of Elimination: About 10% of the nicotine absorbed is excreted unchanged in the urine. Half Life: Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours

USES

用途与制造

Uses

Nicotine is highly toxic alkaloid found in the nightshade family of plants (Solanaceae). (L327) NICOTROL Inhaler is indicated as an aid to smoking cessation for the relief of nicotine withdrawal symptoms. NICOTROL Inhaler therapy is recommended for use as part of a comprehensive behavioral smoking cessation program. It is used for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

ALIASES

名称与别名

共 78 条
3-(1-methylpyrrolidin-2-yl)pyridineDL-NicotineDTXSID3048154CHEBI:1380003-[1-Methylpyrrolidin-2-yl]pyridineRefChem:489602(+-)NICOTINEDTXCID9028128623-834-222083-74-5(+/-)-Nicotine(R,S)-Nicotinerac-Nicotine(RS)-Nicotine(+-)-Nicotine75202-10-7CHEMBL440464destruxolfumeto bacS-(-)-Nicotine

REACTIONS

相关反应

61
HRID 11750 反应方程式

uspto-grants-2006_08 · 10.6084/m9.figshare.5104873.v1 · US07098331B2

查看
HRID 15380 反应方程式

uspto-grants-2010_06 · 10.6084/m9.figshare.5104873.v1 · US07732607B2

查看
HRID 31084 反应方程式

uspto-grants-2008_09 · 10.6084/m9.figshare.5104873.v1 · US07425561B2

查看
HRID 44666 反应方程式

uspto-grants-2013_09 · 10.6084/m9.figshare.5104873.v1 · US08541447B2

查看
HRID 55545 反应方程式

uspto-grants-1997_04 · 10.6084/m9.figshare.5104873.v1 · US05625070

查看
HRID 59711 反应方程式

uspto-grants-2016_09 · 10.6084/m9.figshare.5104873.v1 · US09440948B2

查看
HRID 175040 反应方程式

Training data from https://doi.org/10.1039/C8SC04228D (6/10) · 10.1039/C8SC04228D

查看
HRID 218056 反应方程式

uspto-grants-2012_06 · 10.6084/m9.figshare.5104873.v1 · US08198296B2

查看